- Home
- GLPG vs FRPT Comparison
GLPG vs FRPT Comparison
Compare GLPG & FRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | FRPT |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GLPG | FRPT |
|---|---|---|
| Price | $32.32 | $62.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 15 |
| Target Price | $31.33 | ★ $77.07 |
| AVG Volume (30 Days) | 86.3K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 169.38 |
| EPS | N/A | ★ 2.38 |
| Revenue | $336,643,201.00 | ★ $1,079,494,000.00 |
| Revenue This Year | $3.61 | $15.47 |
| Revenue Next Year | N/A | $9.95 |
| P/E Ratio | ★ N/A | $26.27 |
| Revenue Growth | 10.31 | ★ 16.34 |
| 52 Week Low | $22.36 | $46.76 |
| 52 Week High | $37.78 | $164.07 |
Technical Indicators
Market Signals| Indicator | GLPG | FRPT |
|---|---|---|
| Relative Strength Index (RSI) | 56.94 | 58.99 |
| Support Level | $30.73 | $62.85 |
| Resistance Level | $32.75 | $66.47 |
| Average True Range (ATR) | 0.60 | 2.46 |
| MACD | 0.07 | 0.09 |
| Stochastic Oscillator | 78.52 | 64.03 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About FRPT Freshpet Inc.
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.